» Articles » PMID: 31057543

Immune-Modulation by the Human Respiratory Syncytial Virus: Focus on Dendritic Cells

Overview
Journal Front Immunol
Date 2019 May 7
PMID 31057543
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The human respiratory syncytial virus (hRSV) is the leading cause of pneumonia in infants and produces a significant burden in the elderly. It can also infect and produce disease in otherwise healthy adults and recurrently infect those previously exposed to the virus. Importantly, recurrent infections are not necessarily a consequence of antigenic variability, as described for other respiratory viruses, but most likely due to the capacity of this virus to interfere with the host's immune response and the establishment of a protective and long-lasting immunity. Although some genes encoded by hRSV are known to have a direct participation in immune evasion, it seems that repeated infection is mainly given by its capacity to modulate immune components in such a way to promote non-optimal antiviral responses in the host. Importantly, hRSV is known to interfere with dendritic cell (DC) function, which are key cells involved in establishing and regulating protective virus-specific immunity. Notably, hRSV infects DCs, alters their maturation, migration to lymph nodes and their capacity to activate virus-specific T cells, which likely impacts the host antiviral response against this virus. Here, we review and discuss the most important and recent findings related to DC modulation by hRSV, which might be at the basis of recurrent infections in previously infected individuals and hRSV-induced disease. A focus on the interaction between DCs and hRSV will likely contribute to the development of effective prophylactic and antiviral strategies against this virus.

Citing Articles

Short-Chain Fatty Acids: Promising Therapeutic Targets for Respiratory Syncytial Virus Infection.

Liang M, Dong Q, Wu W, Fan J Clin Rev Allergy Immunol. 2025; 68(1):8.

PMID: 39873814 DOI: 10.1007/s12016-024-09018-x.


Understanding the Relationship of the Human Bacteriome with COVID-19 Severity and Recovery.

Zafar H, Saier Jr M Cells. 2023; 12(9).

PMID: 37174613 PMC: 10177376. DOI: 10.3390/cells12091213.


Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies.

Dvorkin J, De Luca J, Alvarez-Paggi D, Caballero M Infect Drug Resist. 2023; 16:595-605.

PMID: 36733921 PMC: 9888399. DOI: 10.2147/IDR.S373584.


Clinical and biological consequences of respiratory syncytial virus genetic diversity.

Rios Guzman E, Hultquist J Ther Adv Infect Dis. 2022; 9:20499361221128091.

PMID: 36225856 PMC: 9549189. DOI: 10.1177/20499361221128091.


RSV disease in infants and young children: Can we see a brighter future?.

Baraldi E, Lisi G, Costantino C, Heinrichs J, Manzoni P, Ricco M Hum Vaccin Immunother. 2022; 18(4):2079322.

PMID: 35724340 PMC: 9721445. DOI: 10.1080/21645515.2022.2079322.


References
1.
Feldman S, Hendry R, Beeler J . Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol. 1999; 73(8):6610-7. PMC: 112745. DOI: 10.1128/JVI.73.8.6610-6617.1999. View

2.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y . Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767-811. DOI: 10.1146/annurev.immunol.18.1.767. View

3.
Hallak L, Collins P, Knudson W, Peeples M . Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology. 2000; 271(2):264-75. DOI: 10.1006/viro.2000.0293. View

4.
Behera A, Matsuse H, Kumar M, Kong X, Lockey R, Mohapatra S . Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun. 2001; 280(1):188-95. DOI: 10.1006/bbrc.2000.4093. View

5.
Cane P . Molecular epidemiology of respiratory syncytial virus. Rev Med Virol. 2001; 11(2):103-16. DOI: 10.1002/rmv.305. View